CGEN
Price
$1.44
Change
+$0.05 (+3.60%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
130.19M
68 days until earnings call
NCNA
Price
$0.04
Change
-$0.00 (-0.00%)
Updated
May 23 closing price
Capitalization
238.64K
Interact to see
Advertisement

CGEN vs NCNA

Header iconCGEN vs NCNA Comparison
Open Charts CGEN vs NCNABanner chart's image
Compugen
Price$1.44
Change+$0.05 (+3.60%)
Volume$1.45K
Capitalization130.19M
NuCana
Price$0.04
Change-$0.00 (-0.00%)
Volume$77.75M
Capitalization238.64K
CGEN vs NCNA Comparison Chart
Loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGEN vs. NCNA commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a StrongBuy and NCNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (CGEN: $1.39 vs. NCNA: $0.04)
Brand notoriety: CGEN and NCNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 1% vs. NCNA: 40%
Market capitalization -- CGEN: $130.19M vs. NCNA: $238.64K
CGEN [@Biotechnology] is valued at $130.19M. NCNA’s [@Biotechnology] market capitalization is $238.64K. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 1 FA rating(s) are green whileNCNA’s FA Score has 1 green FA rating(s).

  • CGEN’s FA Score: 1 green, 4 red.
  • NCNA’s FA Score: 1 green, 4 red.
According to our system of comparison, both CGEN and NCNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 6 TA indicator(s) are bullish while NCNA’s TA Score has 3 bullish TA indicator(s).

  • CGEN’s TA Score: 6 bullish, 2 bearish.
  • NCNA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CGEN is a better buy in the short-term than NCNA.

Price Growth

CGEN (@Biotechnology) experienced а +1.46% price change this week, while NCNA (@Biotechnology) price change was -24.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was -3.91%.

Reported Earning Dates

CGEN is expected to report earnings on Jul 31, 2025.

NCNA is expected to report earnings on Mar 20, 2025.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGEN($130M) has a higher market cap than NCNA($239K). CGEN YTD gains are higher at: -9.150 vs. NCNA (-96.605). CGEN has higher annual earnings (EBITDA): -14.41M vs. NCNA (-29.33M). CGEN has more cash in the bank: 103M vs. NCNA (11.4M). NCNA has less debt than CGEN: NCNA (221K) vs CGEN (2.91M). CGEN has higher revenues than NCNA: CGEN (27.9M) vs NCNA (0).
CGENNCNACGEN / NCNA
Capitalization130M239K54,393%
EBITDA-14.41M-29.33M49%
Gain YTD-9.150-96.6059%
P/E Ratio64.00N/A-
Revenue27.9M0-
Total Cash103M11.4M904%
Total Debt2.91M221K1,318%
FUNDAMENTALS RATINGS
CGEN vs NCNA: Fundamental Ratings
CGEN
NCNA
OUTLOOK RATING
1..100
1087
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
7
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9297
PRICE GROWTH RATING
1..100
8199
P/E GROWTH RATING
1..100
20100
SEASONALITY SCORE
1..100
9550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NCNA's Valuation (7) in the Biotechnology industry is significantly better than the same rating for CGEN (77). This means that NCNA’s stock grew significantly faster than CGEN’s over the last 12 months.

NCNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CGEN (100). This means that NCNA’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's SMR Rating (92) in the Biotechnology industry is in the same range as NCNA (97). This means that CGEN’s stock grew similarly to NCNA’s over the last 12 months.

CGEN's Price Growth Rating (81) in the Biotechnology industry is in the same range as NCNA (99). This means that CGEN’s stock grew similarly to NCNA’s over the last 12 months.

CGEN's P/E Growth Rating (20) in the Biotechnology industry is significantly better than the same rating for NCNA (100). This means that CGEN’s stock grew significantly faster than NCNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENNCNA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 9 days ago
79%
Declines
ODDS (%)
Bearish Trend 17 days ago
89%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ASR346.01N/A
N/A
Grupo Aeroportuario del Sureste SA
AAOI17.07N/A
N/A
Applied Optoelectronics
XNET5.81N/A
N/A
Xunlei Limited
BBAR21.82N/A
N/A
Banco BBVA Argentina SA
BHFAN16.17-0.06
-0.40%
Brighthouse Financial

CGEN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NURPF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NURPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
N/A
NURPF - CGEN
46%
Loosely correlated
N/A
ASPHF - CGEN
41%
Loosely correlated
N/A
ORMP - CGEN
40%
Loosely correlated
N/A
BDTX - CGEN
40%
Loosely correlated
+1.48%
ITOS - CGEN
37%
Loosely correlated
+5.72%
More

NCNA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NCNA has been closely correlated with RNAC. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NCNA jumps, then RNAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NCNA
1D Price
Change %
NCNA100%
N/A
RNAC - NCNA
93%
Closely correlated
-1.45%
AGEN - NCNA
93%
Closely correlated
N/A
SNPX - NCNA
92%
Closely correlated
-3.86%
ALLR - NCNA
86%
Closely correlated
-1.39%
NRXP - NCNA
85%
Closely correlated
+2.28%
More